Dosing of U-100 insulin and associated outcomes among medicare enrollees with type 1 or type 2 diabetes

Clinical Interventions in Aging

Volumn 10, Issue , 2015, Pages 991-1001

  Eby, Elizabeth L ^a   Van Brunt, Kate ^a   Brusko, Cynthia ^b   Curtis, Bradley ^a   Lage, Maureen J ^c  

^a ELI LILLY AND COMPANY   (United States)

^b Lilly Corporate Center   (United States)

^c Health Metrics Out comes Research LLC   (United States)

Author keywords

Adherence; Costs; Diabetes; Hypoglycemia; Insulin; Resource utilization

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

AGE; AGED; COMORBIDITY; COST; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; ECONOMICS; FEMALE; HEALTH SERVICE; HUMAN; INSURANCE; MALE; MEDICARE; MEDICATION COMPLIANCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES; UTILIZATION; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; COMORBIDITY; COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEALTH SERVICES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSURANCE CLAIM REVIEW; MALE; MEDICARE; MEDICATION ADHERENCE; MODELS, ECONOMETRIC; RETROSPECTIVE STUDIES; SEX FACTORS; UNITED STATES;

EID: 84934287657     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S76398     Document Type: Article

References (46)

1. Centers for Disease Control and Prevention. CDC – State of Aging and Health in America (SAHA) – Aging – Healthy Aging for Older Adults; 2013. Available from: http://www.cdc.gov/aging/help/dph-aging/state-aging-health.html. Accessed April 3, 2014.
2. U. S. Census Bureau DIS. 2012 National Population Projections: Sum­mary Tables; 2013. Available from: http://www.census.gov/population/projections/data/national/2012/summarytables.html. Accessed April 3, 2014.
3. American Diabetes Association. Non-Modifiable Risk Factors – DiabetesPro – American Diabetes Association. DiabetesPro Profes­sional Resources Online; 2014. Available from: http://www.professional.diabetes.org/ResourcesForProfessionals.aspx?typ=17&cid=60390. Accessed April 5, 2014.
4. Centers for Disease Control and Prevention. National Diabetes Statis­tics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 2014. Available at http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf.
5. Sue Kirkman M, Briscoe VJ, Clark N, et al. Diabetes in older adults: a consensus report. J Am Geriatr Soc. 2012;60(12):2342–2356. doi:10.1111/jgs.12035.
6. Zhang X, Decker FH, Luo H, et al. Trends in the prevalence and comorbidities of diabetes mellitus in nursing home residents in the United States: 1995–2004. J Am Geriatr Soc. 2010;58(4):724–730. doi:10.1111/j.1532-5415.2010.02786.x.
7. California Healthcare Foundation/American Geriatrics Society Panel in Improving Care for Elders with Diabetes C. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51(5s):265–280. doi:10.1046/j.1532-5415.51.5s.1.x.
8. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Dia Care. 2013;36(4):1033–1046. doi:10.2337/dc12-2625.
9. American Diabetes Association. Standards of medical care in diabetes – 2014. Dia Care. 2014;37(suppl 1):S14–S80. doi:10.2337/dc14-S014.
10. American Diabetes Association. Standards of medical care in diabetes – 2012. Dia Care. 2012;35(suppl 1):S11–S63. doi:10.2337/dc12-s011.
11. American Diabetes Association. Type 1 Diabetes – American Diabetes Association®. American Diabetes Association; 2014. Available from: http://www.diabetes.org/diabetes-basics/type-1/. Accessed April 5, 2014.
12. Fravel MA, McDanel DL, Ross MB, Moores KG, Starry MJ. Spe­cial considerations for treatment of type 2 diabetes mellitus in the elderly. Am J Health Syst Pharm. 2011;68(6):500–509. doi:10.2146/ajhp080085.
13. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyper­glycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Dia Care. 2012;35(6):1364–1379. doi:10.2337/dc12-0413.
14. Johnson EL, Brosseau JD, Soule M, Kolberg J. Treatment of diabetes in long-term care facilities: a primary care approach. Clin Diabetes. 2008;26(4):152–156. doi:10.2337/diaclin.26.4.152.
15. Sinclair AJ. Special considerations in older adults with diabetes: meet­ing the challenge. Diabetes Spectr. 2006;19(4):229–233. doi:10.2337/diaspect.19.4.229.
16. American Diabetes Association. Insulin administration. Dia Care. 2002;25(suppl 1):s112–s115. doi:10.2337/diacare.25.2007.S112.
17. BD. Different Types of Insulin. BD Helping all people live healthy lives; 2014. Available from: http://www.bd.com/us/diabetes/page.aspx?cat=7001&id=7245. Accessed April 5, 2014.
18. Clark A. USPharmacist.com > U-500 Insulin: Not for Ordinary Use; 2010. Available from: http://www.uspharmacist.com/content/s/126/c/20822/. Accessed April 5, 2014.
19. U.S. Bureau of Labor Statistics. U.S. Bureau of Labor Statistics. Data­bases, Tables & Calculators by Subject. Available from http://www.bls.gov/data/.
20. D’Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assess­ment: the Charlson comorbidity index. Methods Inf Med. 1993;32(5):382–387.
21. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defin­ing comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
22. Touraille P, Gouyon P-H. Why are women smaller than men? When anthropology meets evolutionary biology. Nat Preced. 2008;(713). doi:10.1038/npre.2008.1832.1.
23. Gill G, Hardy K, Lorains J. Relationship between insulin dose, body weight and glycaemic control in insulin-dependent diabetes. Pract Diab Int. 1994;11(6):248–249. doi:10.1002/pdi.1960110609.
24. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyper­glycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379. doi:10.2337/dc12-0413.
25. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implica­tions of recent clinical trials. Ann Intern Med. 2011;154(8):554–559. doi:10.7326/0003-4819-154-8-201104190-00007.
26. Bale GS, Entmacher PS. Estimated life expectancy of diabetics. Diabetes. 1977;26(5):434–438.
27. Lipska KJ, Ross JS, Wang Y, et al. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med. 2014;174(7):1116–1124. doi:10.1001/jamainternmed.2014.1824.
28. Kabadi MU, Kabadi UM. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. Ann Pharmacother. 2003;37(11):1572–1576. doi:10.1345/aph.1C492.
29. Daousi C, Casson IF, Gill GV, MacFarlane IA, Wilding JPH, Pinkney JH. Prevalence of obesity in type 2 diabetes in secondary care: associa­tion with cardiovascular risk factors. Postgrad Med J. 2006;82(966): 280–284. doi:10.1136/pmj.2005.039032.
30. Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabe­tes care. Dia Care. 2006;29(3):725–731. doi:10.2337/diacare.29.03.06.dc05-2078.
31. Pentakota SR, Rajan M, Fincke BG, et al. Does diabetes care differ by type of chronic comorbidity?: An evaluation of the Piette and Kerr framework. Dia Care. 2012;35(6):1285–1292. doi:10.2337/dc11-1569.
32. Ahren B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag. 2013;9:155–163. doi:10.2147/VHRM.S33934.
33. Tunis SL, Ascher-Svanum H, Stensland M, Kinon BJ. Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs. Pharmacoeconomics. 2004;22(1):1–8.
34. Da Costa S, Brackenridge B, Hicks D. A comparison of insulin pen use in the United States and the United Kingdom. Diabetes Educ. 2002;28(1):52–56
35. Grimmer K, Beaton K, Kumar S, et al. Estimating the risk of functional decline in the elderly after discharge from an Australian public tertiary hospital emergency department. Aust Health Rev. 2013;37(3):341–347. doi:10.1071/AH12034.
36. McCusker J, Verdon J. Do geriatric interventions reduce emergency department visits? A systematic review. J Gerontol A Biol Sci Med Sci. 2006;61(1):53–62.
37. Fonseca VA. Defining and Characterizing the Progression of Type 2 Diabetes. Dia Care. 2009;32(suppl 2):S151–S156. doi:10.2337/dc09-S301.
38. Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Dia Care. 2005;28(5):1240–1244. doi:10.2337/diacare.28.5.1240.
39. Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longi­tudinal cohort study. Clin Ther. 2003;25(11):2958–2971.
40. Curkendall SM, Thomas N, Bell KF, Juneau PL, Weiss AJ. Predictors of medication adherence in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2013;29(10):1275–1286. doi:10.1185/03007995.2013.821056.
41. García-Pérez L-E, Alvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–194. doi:10.1007/s13300-013-0034-y.
42. Nau DP. Recommendations for improving adherence to type 2 diabetes mellitus therapy – focus on optimizing oral and non-insulin therapies. Am J Manag Care. 2012;18(suppl 3):S49–S54.
43. Eby EL, Zagar AJ, Wang P, et al. Healthcare costs and adherence associated with human regular u-500 versus high-dose u-100 insulin in patients with diabetes. Endocr Pract. 2014;20(7):663–670. doi:10.4158/EP13407.OR.
44. Eby EL, Wang P, Curtis BH, et al. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insu­lin: a retrospective database analysis. J Med Econ. 2013;16(4):529–538. doi:10.3111/13696998.2013.772059.
45. Rubin DJ, Rybin D, Doros G, McDonnell ME. Weight-based, insulin dose-related hypoglycemia in hospitalized patients with diabetes. Diabetes Care. 2011;34(8):1723–1728. doi:10.2337/dc10-2434.
46. Reach G, Zerrouki A, Leclercq D, d’ Ivernois J-F. Adjusting insulin doses: from knowledge to decision. Patient Educ Couns. 2005;56(1):98–103. doi:10.1016/j.pec.2004.01.001.